HIV感染对肝细胞癌自然病史的影响:一项全球多队列研究结果
这项国际多队列研究纳入四大洲未接受抗癌治疗的1588例肝细胞癌患者,其中132例HIV阳性。校正分期、肝功能、甲胎蛋白、地理来源和性别后,HIV血清阳性使死亡风险增加24%(P=0.0333),中位总生存为2.2个月 vs 4.1个月。作者结论认为HIV血清阳性与肝细胞癌生存下降相关,需开展免疫生物学机制研究。
要点
- 未接受抗癌治疗的肝细胞癌患者中,HIV阳性者中位OS为2.2个月,HIV阴性者为4.1个月。
- 校正BCLC分期、CTP分级、甲胎蛋白、地理来源和男性性别后,HIV血清阳性使死亡风险增加24%(P=0.0333)。
- HIV阳性患者中,CTP(P=0.0071)和甲胎蛋白(P<0.0001)是更差OS的预测因素。
核心结论
- 尽管接受了充分的抗逆转录病毒治疗,HIV血清阳性仍与肝细胞癌患者生存下降相关,且独立于分期、抗癌治疗和地理来源。
- 作者认为亟需开展研究HIV相关肝细胞癌免疫生物学的机制研究。
研究设计与样本
- 国际多队列研究,纳入来自四大洲、未接受任何抗癌治疗的肝细胞癌患者。
- 共招募1588例患者,其中132例为HIV阳性。
- 采用单因素和多因素模型评估HIV血清阳性对总生存的影响,并校正常见预后因素和人口学特征。
主要发现
- 多数患者符合BCLC C或D期标准(n=1168[74%]),Child-Turcotte-Pugh(CTP)B级(中位评分7;四分位距[IQR]3)。
- 诊断肝细胞癌时,多数HIV阳性患者(n=65[64%])已接受抗逆转录病毒治疗,中位持续时间8.3年(IQR 8.59年),中位CD4+细胞计数256(IQR 284),HIV RNA检测不到者n=68[52%]。
- 总生存随BCLC 0至D期显著下降(分别为16、12、7.5、3.1和3个月;P<.001)。
- HIV阳性患者中位OS为HIV阴性者的一半(2.2个月[bootstrap 95%CI 1.2至3.1个月] vs 4.1个月[95%CI 3.6至4.4个月])。
- 校正分析中,HIV血清阳性使死亡风险增加24%(P=.0333),独立于BCLC(P<.0001)、CTP(P<.0001)、甲胎蛋白(P<.0001)、地理来源(P<.0001)和男性性别(P=.0016)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Conflicting evidence indicates that HIV seropositivity may influence the outcome of patients with hepatocellular carcinoma (HCC), a leading cause of mortality in people with HIV. We aimed to verify whether HIV affected the overall survival (OS) of patients with HCC, independent of treatment and geographic origin. PATIENTS AND METHODS: We designed an international multicohort study of patients with HCC accrued from four continents who did not receive any anticancer treatment. We estimated the effect of HIV seropositivity on patients' OS while accounting for common prognostic factors and demographic characteristics in uni- and multivariable models. RESULTS: A total of 1,588 patients were recruited, 132 of whom were HIV positive. Most patients clustered within Barcelona Clinic Liver Cancer (BCLC) C or D criteria (n = 1,168 [74%]) and Child-Turcotte-Pugh (CTP) class B (median score, 7; interquartile range [IQR], 3). At HCC diagnosis, the majority of patients who were HIV-positive (n = 65 [64%]) had been on antiretrovirals for a median duration of 8.3 years (IQR, 8.59 years) and had median CD4+ cell counts of 256 (IQR, 284) with undetectable HIV RNA (n = 68 [52%]). OS decreased significantly throughout BCLC stages 0 to D (16, 12, 7.5, 3.1, and 3 months, respectively; P < .001). Median OS of patients who were HIV-positive was one half that of their HIV-uninfected counterparts (2.2 months [bootstrap 95% CI, 1.2 to 3.1 months] v 4.1 months [95% CI, 3.6 to 4.4 months]). In adjusted analyses, HIV seropositivity increased the hazard of death by 24% ( P = .0333) independent of BCLC ( P < .0001), CTP ( P < .0001), α-fetoprotein ( P < .0001), geographical origin ( P < .0001), and male sex ( P = .0016). Predictors of worse OS in patients who were HIV-positive included CTP ( P = .0071) and α-fetoprotein ( P < .0001). CONCLUSION: Despite adequate antiretroviral treatment, HIV seropositivity is associated with decreased survival in HCC, independent of stage, anticancer treatment, and geographical origin. Mechanistic studies investigating the immunobiology of HIV-associated HCC are urgently required.
引用
- Pinato DJ, Allara E, Chen TY, et al. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. J Clin Oncol. 2018. PMID: 30562130. doi:10.1200/JCO.18.00885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。